{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,10,15]],"date-time":"2023-10-15T08:57:10Z","timestamp":1697360230235},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2005,4,1]],"date-time":"2005-04-01T00:00:00Z","timestamp":1112313600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Chirurg"],"published-print":{"date-parts":[[2005,4]]},"DOI":"10.1007\/s00104-004-0906-9","type":"journal-article","created":{"date-parts":[[2004,8,11]],"date-time":"2004-08-11T05:52:36Z","timestamp":1092203556000},"page":"353-358","source":"Crossref","is-referenced-by-count":2,"title":["Medikament\ufffdse Therapie der gastro\ufffdsophagealen Refluxkrankheit"],"prefix":"10.1007","volume":"76","author":[{"given":"H.","family":"Koop","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"CR1","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1046\/j.1365-2036.2000.00840.x","volume":"14","author":"Adachi","year":"2000","unstructured":"Adachi K, Katsube T, Kawamura A et al. (2000) CYP 2C19 genotype status and intragstric pH during dosing with lasoprazole and rabeprazole. Aliment Pharmacol Ther 14:1259?1266","journal-title":"Aliment Pharmacol Ther"},{"key":"CR2","first-page":"2849","volume":"96","author":"Armstrong","year":"2001","unstructured":"Armstrong D, Par\u00e9 P, Pericak DM et al. (2001) Symptom relief in gastroesophageal reflux disease: a randomized, controlled comparison of pantoprazole and nizatidine in a mixed patient population with erosive esophagitis or endoscopy-negative reflux disease. Am J Gastroenterol 96:2849?2857","journal-title":"Am J Gastroenterol"},{"key":"CR3","doi-asserted-by":"crossref","unstructured":"Blum AL, Martinek J (1999) Interactions of proton pump inhibitors and Helicobacter pylori in vivo. In: Olbe L (ed) Proton Pump Inhibitors. Birkh\u00e4user, Basel Boston London, S\u00a0130?141","DOI":"10.1007\/978-3-0348-8795-3_8"},{"key":"CR4","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1046\/j.1365-2036.1997.00167.x","volume":"11","author":"Carlsson","year":"1997","unstructured":"Carlsson R, Galmiche JP, Dent J, Lundell L, Frison L (1997) Prognostic factors influencing relapse of oesophagitis during maintenance therapy with antisecretory drugs: a meta-analysis of long-term omeprazole trials. Aliment Pharmacol Ther 11:473?482","journal-title":"Aliment Pharmacol Ther"},{"key":"CR5","doi-asserted-by":"crossref","unstructured":"Carlsson R, Holloway RH (2000) Endoscopy-negative reflux disease. Balliere?s Clin Gastroenterol 14:827?837","DOI":"10.1053\/bega.2000.0127"},{"key":"CR6","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/S0149-2918(01)80087-4","volume":"23","author":"Caro","year":"2001","unstructured":"Caro JJ, Salas M, Ward A (2001) Healing and relapse rates in gastroesophageal reflux disease treated with newer proton pump inhibitors lansoprazole, rabeprazole, and pantoprazole compared with omeprazole, ranitidine, and placebo: evidence from randomized clinical trials. Clin Ther 23:998?1017","journal-title":"Clin Ther"},{"key":"CR7","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1111\/j.1572-0241.2002.05532.x","volume":"97","author":"Castell","year":"2002","unstructured":"Castell DO, Kahrilas PJ, Richter JE et al. (2002) Esomeprazole (40\u00a0mg) compared with lansoprazole (30\u00a0mg) in the treatment of erosive esophagitis. Am J Gastroenterol 97:575?583","journal-title":"Am J Gastroenterol"},{"key":"CR8","doi-asserted-by":"crossref","first-page":"1798","DOI":"10.1053\/gast.1997.v112.pm9178669","volume":"112","author":"Chiba","year":"1997","unstructured":"Chiba N, de Gara CJ, Wilkinson JM, Hunt RH (1997) Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: a meta-analysis. Gastroenetrology 112:1798?1810","journal-title":"Gastroenetrology"},{"key":"CR9","doi-asserted-by":"crossref","unstructured":"Dent J, Brun J, Fendrick AM et al. (1999) An evidence-based apprisial of reflux disease management?the Genval Workshop Report. Gut 44 [Suppl\u00a02]:1?16","DOI":"10.1136\/gut.44.2008.S1"},{"key":"CR10","first-page":"467","volume":"7","author":"Eriksson","year":"1995","unstructured":"Eriksson S, Langstr\u00f6m G, Rikner L, Carlsson R, Naesdal J (1995) Omeprazole and H2-receptor antagonists in the acute treatment of duodenal ulcer, gastric ulcer and reflux oesophagitis: a meta-analysis. Eur J Gastroenetrol Hepatol 7:467?475","journal-title":"Eur J Gastroenetrol Hepatol"},{"key":"CR11","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1111\/j.1440-1746.1996.tb00269.x","volume":"11","author":"Jaspersen","year":"1996","unstructured":"Jaspersen D, Schwacha H, Schorr W, Brennenstuhl M, Raschka C, Hammar CH (1996) Omeprazole in the treatment of patients with complicated gastrooesophageal reflux disease. J Gastroenterol Hepatol 11:897?899","journal-title":"J Gastroenterol Hepatol"},{"key":"CR12","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1046\/j.1365-2036.2003.01562.x","volume":"17","author":"Klok","year":"2003","unstructured":"Klok RM, Postma MJ, van Hout BA, Brouwers JR (2003) Meta-analysis: comparing the efficacy of proton pump inhibitors in short-term use. Aliment Pharmacol Ther 17:1237?1245","journal-title":"Aliment Pharmacol Ther"},{"key":"CR13","first-page":"566","volume":"86","author":"Koop","year":"1991","unstructured":"Koop H, Katschinski M, Arnold R (1991) Konservative Behandlung der floriden peptischen \u00d6sophagusstenose. Vollst\u00e4ndige Beseitigung durch Bougierung und Omeprazol bei H2-Blocker-refrakt\u00e4ren F\u00e4llen. Med Klin 86:566?568","journal-title":"Med Klin"},{"key":"CR14","unstructured":"Labenz J, Keeling N, Eklund S, Naucler E (2003 ) A comparison of esomeprazole 40\u00a0mg once daily and pantoprazole 40\u00a0mg once daily for the healing of erosive esophagitis. 11th United European Gastroenterology Week, Madrid [Abstr]"},{"key":"CR15","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1046\/j.1365-2036.2003.01550.x","volume":"17","author":"Labenz","year":"2003","unstructured":"Labenz J, Petersen KU, R\u00f6sch W, Koeltz HR (2003) A summary of Food and Drug Administration-reported adverse events and drug interactions occurring during therapy with omeprazole, lansoprazole and pantoprazole. Aliment Pharmacol Ther 17:1015?1019","journal-title":"Aliment Pharmacol Ther"},{"key":"CR16","doi-asserted-by":"crossref","unstructured":"Lundell L, Dent J (1999) Gastro-oesophageal reflux disease. In: Olbe L (ed) Proton Pump Inhibitors. Birkh\u00e4user, Basel Boston London, S\u00a0223?235","DOI":"10.1007\/978-3-0348-8795-3_14"},{"key":"CR17","doi-asserted-by":"crossref","first-page":"2616","DOI":"10.1111\/j.1572-0241.2003.08783.x","volume":"98","author":"Miner","year":"2003","unstructured":"Miner P, Katz PO, Chen Y, Sostek M (2003) Gastric acid control with esomeprazole, lansoprazole, omeprazole, pantoprazole, and rabeprazole: a five-way crossover study. Am J Gastroenterol 98:2616?2620","journal-title":"Am J Gastroenterol"},{"key":"CR18","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1053\/gast.1999.0029900327","volume":"117","author":"Ouatu-Lescar","year":"1999","unstructured":"Ouatu-Lescar R, Fitzgerald RC, Triadafilopoulos G (1999) Differentiation and proliferation in Barrett?s esophagus and the effect of acid suppression. Gastroenterology 117:327?335","journal-title":"Gastroenterology"},{"key":"CR19","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1136\/gut.45.4.489","volume":"45","author":"Peters","year":"1999","unstructured":"Peters FTM, Ganesh S, Kuipers EJ et al. (1999) Endoscopic regression of Barrett?s oesophagus during omeprazole treatment: a randomised double blind study. Gut 45:489?494","journal-title":"Gut"},{"key":"CR20","doi-asserted-by":"crossref","unstructured":"van Pinxteren B, Numans ME, Bonis PA, Lau J (2001) Short-term treatment with proton pump inhibitors, H2-receptor antagonists and prokinetics for gastro-oesophageal reflux disease-like symptoms and endoscopy negative reflux disease. Cochrane Database Syst Rev CD 002095","DOI":"10.1002\/14651858.CD002095"},{"key":"CR20a","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1046\/j.1525-1497.2003.20833.x","volume":"18","author":"Van","year":"2003","unstructured":"Van Pinxteren B, Numans ME, Lau J, de Wit NJ, Hungin AP, Bonis PAL (2003) Short-term treatment of gastroesophageal reflux disease. J Gen Intern Med 18:755?763","journal-title":"J Gen Intern Med"},{"key":"CR21","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/S0016-5107(96)70319-X","volume":"43","author":"Silvis","year":"1996","unstructured":"Silvis SE, Farahmand M, Johnson JA, Ansel HJ, Ho SB (1996) A randomized blinded comparison of omeprazole and ranitidine in the treatment of chronic esophageal stricture secondary to acid peptic reflux. Gastrointest Endoc 43:216?221","journal-title":"Gastrointest Endoc"},{"key":"CR22","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1016\/0016-5085(94)90562-2","volume":"107","author":"Smith","year":"1994","unstructured":"Smith PM, Kerr GD, Cockel R et al. (1994) A comparison of omeprazole and ranitidine in the prevention of recurrance of benign esophageal stricture. Restore Investigator Group. Gastroenterology 107:1545?1548","journal-title":"Gastroenterology"},{"key":"CR23","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1046\/j.1365-2036.2001.00943.x","volume":"15","author":"Talley","year":"2001","unstructured":"Talley NJ, Lauritsen K, Tunturi-Hahnala H et al. (2001) Esomeprazole 20\u00a0mg maintains symptom control in endoscopy-negative gastro-oesophageal reflux disease: a controlled trial of ?on-demand? therapy for 6 months. Aliment Pharmacol Ther 15:347?354","journal-title":"Aliment Pharmacol Ther"},{"key":"CR24","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1056\/NEJM199510263331703","volume":"333","author":"Vigneri","year":"1995","unstructured":"Vigneri S, Termini R, Leandro G et al. (1995) A comparison of five maintenance therapies for reflux esophagitis. N Engl J Med 333:1106?1110","journal-title":"N Engl J Med"}],"container-title":["Der Chirurg"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00104-004-0906-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00104-004-0906-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00104-004-0906-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,2]],"date-time":"2020-04-02T23:34:36Z","timestamp":1585870476000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00104-004-0906-9"}},"subtitle":["Eine evidenzbasierte \ufffdbersicht"],"short-title":[],"issued":{"date-parts":[[2005,4]]},"references-count":25,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2005,4]]}},"alternative-id":["906"],"URL":"https:\/\/doi.org\/10.1007\/s00104-004-0906-9","relation":{},"ISSN":["0009-4722","1433-0385"],"issn-type":[{"value":"0009-4722","type":"print"},{"value":"1433-0385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,4]]}}}